Search research articles
Contact Us
Filters
Showing results (61-70 of 65) with videos related to
Page
of 7
Sort By:
You have reached the last page of results.
This site can display upto 65 results.
Stem Cells (Dayton, Ohio)
|
March 25, 2006
Transplantation of human embryonic stem cell-derived cells to a rat model of Parkinson's disease: effect of in vitro differentiation on graft survival and teratoma formation
Anke Brederlau, Ana Sofia Correia, Sergey V Anisimov, et al.
Neurology and Therapy
|
May 7, 2026
Real-World Safety and Effectiveness of 24-Hour Foslevodopa/Foscarbidopa in Parkinson's Disease: ROSSINI Study 6-Month Interim Results
Wolfgang H Jost, Filip Bergquist, Andrew Evans, et al.
Clinical Parkinsonism & Related Disorders
|
February 29, 2024
Continuous subcutaneous foslevodopa/foscarbidopa infusion for the treatment of motor fluctuations in Parkinson's disease: Considerations for initiation and maintenance
Victor S C Fung, Jason Aldred, Martha P Arroyo, et al.
Neurology and Therapy
|
October 10, 2023
Correction: Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson's Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study
Jason Aldred, Eric Freire-Alvarez, Alexander V Amelin, et al.
Neurology and Therapy
|
August 26, 2023
Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson's Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study
Jason Aldred, Eric Freire-Alvarez, Alexander V Amelin, et al.
Page
of 7
Search research articles
Search
Showing results (61-70 of 65) with videos related to
Sort By:
Page
of 7
You have reached the last page of results.
This site can display upto 65 results.
Stem Cells (Dayton, Ohio)
|
March 25, 2006
Transplantation of human embryonic stem cell-derived cells to a rat model of Parkinson's disease: effect of in vitro differentiation on graft survival and teratoma formation
Anke Brederlau, Ana Sofia Correia, Sergey V Anisimov, et al.
Neurology and Therapy
|
May 7, 2026
Real-World Safety and Effectiveness of 24-Hour Foslevodopa/Foscarbidopa in Parkinson's Disease: ROSSINI Study 6-Month Interim Results
Wolfgang H Jost, Filip Bergquist, Andrew Evans, et al.
Clinical Parkinsonism & Related Disorders
|
February 29, 2024
Continuous subcutaneous foslevodopa/foscarbidopa infusion for the treatment of motor fluctuations in Parkinson's disease: Considerations for initiation and maintenance
Victor S C Fung, Jason Aldred, Martha P Arroyo, et al.
Neurology and Therapy
|
October 10, 2023
Correction: Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson's Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study
Jason Aldred, Eric Freire-Alvarez, Alexander V Amelin, et al.
Neurology and Therapy
|
August 26, 2023
Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson's Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study
Jason Aldred, Eric Freire-Alvarez, Alexander V Amelin, et al.
Page
of 7